If you want to read more about Oshis approach and impact on GLP-1 patients, download our full case study here.
So frustrating Reply I meet all requirements for the Bridge Program
This pricing dynamic constrains overall market penetration and slows adoption despite the strong clinical benefits of GLP-1 therapies in weight management and glycemic control, making cost a key obstacle to broader global uptake
adults to understand more about GLP-1 adoption, how they change spending behaviors, and how GLP-1 trends may impact Americans' everyday budgets
One limitation worth stating plainly: this option currently exists only for the semaglutide family
These compounded versions arent the same and may act differently in the body than the FDA-approved semaglutide and tirzepatide and, thus, cause harm. Semaglutides can help with weight loss, but they shouldnt be used for short-term weight loss